Core Viewpoint - Fujian Pharmaceutical is experiencing significant operational improvement in 2025, driven primarily by its lithium battery electrolyte additive business, which has benefited from rising demand in the power battery and energy storage markets [1][5]. Group 1: Business Performance - The lithium battery electrolyte additive products, such as VC and FEC, saw a substantial price increase in Q4 2025, with battery-grade VC averaging 164,000 yuan/ton, up over 200% from the low in September [1]. - The pharmaceutical manufacturing segment has optimized steadily despite intense market competition, with a decrease in the price of key raw materials like 6-APA, leading to an improvement in gross margins [1][2]. - The company reported a net loss of 39 million to 57 million yuan for the year, marking a significant reduction in losses, and achieved profitability in Q4, indicating a positive trend in operational performance [5]. Group 2: Future Outlook - The synthetic biological microbial protein business achieved critical breakthroughs in 2025, obtaining multiple certifications that pave the way for large-scale production, although its contribution to 2025's performance is limited [3]. - For 2026, the company plans to consolidate its market position in pharmaceuticals, leverage price increases in the new energy sector, and accelerate the development of the microbial protein project to enhance capacity and market presence [3].

Core Viewpoint - Fuxiang Pharmaceutical (300497.SZ) expects a loss of 39 million to 57 million yuan in 2025, with a non-recurring loss of 69 million to 87 million yuan, and operating revenue projected between 1.15 billion to 1.25 billion yuan [1] Group 1: Business Performance - The company anticipates significant improvement in overall operating performance driven by the synergistic development of its three main business segments in 2025 [1] - The lithium battery electrolyte additive business is expected to benefit from the continuous growth in demand for power batteries and the rapid explosion in energy storage battery demand, leading to a substantial increase in prices of VC and FEC products in Q4 [1] - In the pharmaceutical manufacturing sector, despite intense market competition, the decline in prices of key raw materials such as 6-APA for core products like Tazobactam and Sulbactam is expected to enhance the gross margin of the pharmaceutical business [1] Group 2: Financial Projections - The projected operating revenue for 2025 is estimated to be between 1.15 billion and 1.25 billion yuan [1] - The expected net profit attributable to shareholders of the listed company is anticipated to significantly reduce losses year-on-year due to the improved profitability of the aforementioned business segments [1]

Core Viewpoint - Fuxiang Pharmaceutical (300497) anticipates significant improvement in its financial performance for 2025, projecting revenue between 1.15 billion to 1.25 billion yuan and a reduced net loss of 39 million to 57 million yuan compared to 2024, with a turnaround expected in Q4 2025 [1] Group 1: Business Segments - The company has been deeply involved in the pharmaceutical intermediates and active pharmaceutical ingredients sectors, while also expanding into lithium battery electrolyte additives and synthetic biology microbial protein businesses [1] - The lithium battery electrolyte additive segment is expected to be the main driver of revenue growth in 2025, benefiting from rising demand in the power battery and energy storage markets [1] - The average price of battery-grade VC has increased over 200% since the low point in September 2025, reflecting a tight supply-demand balance in the industry [2] Group 2: Financial Performance - Fuxiang Pharmaceutical has leveraged its scale production capacity and cost control advantages to benefit from the current price increase cycle, resulting in significant improvements in product shipment volume, sales revenue, and gross margin [2] - The pharmaceutical manufacturing segment has seen a reduction in the price of key raw materials, which has alleviated cost pressures and improved gross margins year-on-year [2] - The company has reduced asset impairment provisions, enhancing asset value stability as profitability improves in both its new energy and pharmaceutical businesses [2] Group 3: Future Growth Potential - The synthetic biology microbial protein business has achieved critical breakthroughs in 2025, with multiple certifications obtained, paving the way for compliance from research to large-scale production [3] - Although the microbial protein business is expected to contribute limited revenue in 2025, it is anticipated to become a core profit growth point as production capacity is released and market expansion progresses [3] - The company aims to consolidate its market position in pharmaceuticals, capitalize on price increases in the new energy sector, and accelerate the construction and market deployment of its microbial protein project to drive high-quality development [3]

证券日报网讯 1月26日，富祥药业发布2025年度业绩预告称，公司预计2025年1月1日至2025年12月31日 营业收入115，000万元–125，000万元，上年同期117，785万元；归属于上市公司股东的净利润亏损3， 900万元–5，700万元，上年同期亏损27，210万元。 （编辑 袁冠琳） ...

Core Viewpoint - Fuxiang Pharmaceutical is expected to significantly reduce its net loss in 2025, projecting a loss of 39 million to 57 million yuan, with a potential turnaround to profitability in Q4, driven by the synergy of its three main business segments: new energy, pharmaceutical manufacturing, and synthetic biology [1] Group 1: Business Performance - The new energy lithium battery electrolyte additive business is identified as the core driver of performance growth in 2025, benefiting from rising demand in the power battery and energy storage markets, leading to a substantial price increase for products like VC and FEC in Q4 [1] - The pharmaceutical manufacturing segment has optimized its operations despite intense market competition, with a decrease in the price of key raw materials like 6-APA alleviating cost pressures and improving gross margins [2] - The synthetic biology segment achieved significant milestones in 2025, obtaining key certifications that enable the transition from laboratory research to large-scale production, indicating a successful compliance pathway [2] Group 2: Future Outlook - For 2026, the company aims to consolidate its market position in the pharmaceutical sector while focusing on cost reduction and efficiency improvements [3] - The company plans to capitalize on the rising product prices in the new energy sector by enhancing production capacity through technological upgrades [3] - The company will accelerate the development of the synthetic biology protein project, expanding its application scenarios and enhancing its market presence both domestically and internationally [3]

Group 1 - The core point of the article is that Fuxiang Pharmaceutical announced the pledge of 3,600,000 restricted shares by its controlling shareholder, Bao Jianhua, to Jingdezhen Rural Commercial Bank for personal funding needs [2] - The pledge started on January 23, 2026, and after this transaction, the total pledged shares by Bao Jianhua reached 50,600,000, which accounts for 46.68% of his total holdings [2]

南财智讯1月26日电，富祥药业发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为亏 损3900万元—5700万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损6900 万元—8700万元。业绩变动原因说明：1、2025年，公司三大业务协同发展，带动整体经营业绩改善， 推动归属于上市公司股东的净利润同比大幅减亏，主要得益于：（1）新能源锂电池电解液添加剂业务 方面，受动力电池市场需求持续增长、储能电池需求快速爆发的影响，拉动上游锂电材料需求攀升，促 使VC、FEC等锂电池电解液添加剂产品价格在第四季度大幅上涨。（2）医药制造业务方面，公司医药 产品的市场竞争仍然激烈，但公司医药核心产品他唑巴坦、舒巴坦的主要原材料6-apa等价格下降，推 动医药业务毛利率有所提升。同时随着上述业务盈利状况改善，本报告期相关资产减值准备计提减少。 2、报告期内，预计非经常性损益对公司净利润的影响金额约3000万元。 ...

富祥药业公告，预计2025年度净利润亏损3900万元–5700万元。报告期内，预计非经常性损益对公司净 利润的影响金额约3000万元。 ...

证券代码：300497 证券简称：富祥药业 公告编号：2026-013 江西富祥药业股份有限公司 关于公司控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）近日收到控股股东、实际控制 人包建华先生关于其所持有的公司部分股份质押的通知，具体情况如下： 一、股东部分股份质押的基本情况 注：本次质押股份不负担重大资产重组等业绩补偿业务。 2、股东股份累计被质押的情况 截至本公告披露日，包建华先生及其一致行动人所持股份质押情况如下： | | | | 本次质押前 | 本次质押后 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 持股数量 | 持股 | | | | | 已质押股份 | 占已质 | 未质押股份 | | | 名称 | （股） | 比例 | 质押股份数 | 质押股份数 | 持股份 | 总股本 | 限售和冻结 | 押股份 ...

证券代码：300497 证券简称：富祥药业 公告编号：2026-015 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 1、会议召开情况 江西富祥药业股份有限公司（以下简称："公司"）2026年第一次临时股东会于2026 年1月26日（星期一）下午14:30点在江西省景德镇市昌江区鱼丽工业区2号公司会议室 召开，会议由董事长包建华先生主持。 会议由公司董事会召集，会议采取现场记名投票与网络投票相结合的方式召开， 其中通过深圳证券交易所系统进行网络投票时间为：2026年1月26日上午9:15—9:25， 9:30-11:30，下午13:00—15:00；通过深圳证券交易所互联网投票系统投票的具体时间 为2026年1月26日9:15—15:00的任意时间。 会议的召开及表决等程序符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 江西富祥药业股份有限公司 2026年第一次临时股东会会议决议公告 通过现场和网络投票的股东 269 人，代表 ...